Meeting
2024 ASCO Annual Meeting
High dose chemotherapy in male patients with germ cell cancer: A population-based study by the SWENOTECA group.
Authors
Anna Jansson
Department of Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden
Anna Jansson , Gabriella Elisabeth Cohn-Cedermark , Helene F. S. Negaard , Torgrim Tandstad , Olof Stahl , Annika Hedlund , Asa Karlsdottir , Martin Hellström , Carl Wilhelm Langberg , Camilla Sköld , Hege Sagstuen Haugnes , Ingrid Glimelius
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Germ Cell/Testicular Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5040)
DOI
10.1200/JCO.2024.42.16_suppl.5040
Abstract #
5040
Poster Bd #
358
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT).
First Author: Fadi Taza
Poster
2020 Genitourinary Cancers Symposium
Prognostic significance of rate of tumor marker (TM) decline during high-dose chemotherapy (HDCT) for relapsed germ cell tumors (rGCT).
First Author: Nabil Adra
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2024 ASCO Annual Meeting
Primary intracranial germ cell tumors in adolescents and adults: Results of an international, multicenter, retrospective cohort study.
First Author: Stefanie Zschaebitz